Market Newsdesk

SALT LAKE CITY
, April 7, 2025 /PRNewswire/ — FatPipe, Inc. (“FatPipe” or the “Company”), a pioneer in enterprise-class, application-aware, secure software-defined wide area network (“SD-WAN”) solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and middle-market companies, is pleased to announce the pricing of its underwritten initial public offering of 695,656 shares of common stock at a public offering price of $5.75 per share. The shares of common stock have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on April 8, 2025, under the ticker symbol “FATN.”

The Company expects to receive aggregate gross proceeds of $4 million from the offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 104,348 shares of common stock at the public offering price, less underwriting discounts. The closing for the initial public offering is expected to occur on or about April 9, 2025, subject to satisfaction of customary closing conditions.

D. Boral Capital LLC is acting as the Sole Book-Running Manager for the offering.

Sichenzia Ross Ference Carmel LLP, New York, NY, is acting as counsel to the Company, and Lucosky Brookman LLP, Woodbridge, NJ, is acting as counsel to the underwriter in connection with the offering.

A registration statement on Form S-1 (File No. 333-280925) relating to the offering was filed with the U.S. Securities and Exchange Commission (“SEC”), as amended and was declared effective by the SEC on February 12, 2025. A post-effective amendment to the registration statement on Form S-1 relating to the offering was filed with SEC and was declared effective by the SEC on March 17, 2025. The offering of the securities is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus may be obtained, when available, at the SEC’s website at www.sec.gov or from D. Boral Capital LLC, Attention: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at [email protected], or by telephone at +1(212)-970-5150.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About FatPipe, Inc.

FatPipe, Inc. a pioneer in enterprise-class, application-aware, secure software-defined wide area network (“SD-WAN”) solutions for organizations, including enterprises, communication service providers, security service providers, government organizations, and middle-market companies. FatPipe’s network optimization solutions, along with robust cybersecurity and SASE protection, provide organizations with superior network performance and corporate security.  FatPipe provides highly recognized intra-corporate wide area network solutions that transcend internet and other network failures to maintain business continuity and high transmission security.  FatPipe’s network monitoring, reporting, and alerting, reduce the time and effort required by network administrators leading to more efficient network operations.

FatPipe has customers in the United States and around the world, and more than 200 resellers worldwide including almost all national resellers in the US. 

For more information, please visit https://www.fatpipeinc.com.

Legal Disclaimer

Certain statements contained in this press release, including statements relating to the Company’s expectations regarding the completion, timing and size of its proposed public offering and listing may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on management’s current expectations and are inherently subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the offering and other risks described in FatPipe’s registration statement on Form S-1, as it may be amended from time to time. Except as required by law, FatPipe expressly disclaims a duty to provide updates to forward-looking statements, whether as a result of new information, future events or other occurrences

Company Contact Info

[email protected]

Media Contacts

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fatpipe-inc-nasdaq-fatn-announces-pricing-of-initial-public-offering-and-listing-on-nasdaq-302422477.html

SOURCE FatPipe Networks

AUSTIN, Minn.
, April 7, 2025 /PRNewswire/ — Hormel Foods Corporation (NYSE: HRL), a Fortune 500 global branded food company, announced today that Steve Lykken, group vice president of supply chain, will be leaving the company to pursue another opportunity. Kevin Myers, PhD, has been appointed interim group vice president of supply chain.

Myers joined Hormel Foods in 2001 as a research scientist and has since taken on roles of increasing responsibility. In 2015, he was appointed senior vice president of research & development and quality control, overseeing product development, packaging, food safety sciences and lab services. Before joining the company, Myers spent a decade in the food industry, holding leadership positions in food technology, research science and new product development.

“I am grateful for Steve’s contributions, dedication and leadership over the past 32 years and wish him all the best in his new chapter,” said Jim Snee, president and chief executive officer, Hormel Foods. “We are fortunate to have Kevin, a highly respected and proven leader with deep expertise, stepping into the role of interim group vice president of supply chain. With Kevin at the helm, we remain focused on transforming and modernizing our supply chain, delivering for our customers and driving operational excellence.”

Under the interim structure, Myers will oversee all aspects of the company’s supply chain organization including procurement, manufacturing, engineering, logistics, research and development, quality management and plant operations. A permanent replacement for Lykken will be decided by the company’s future chief executive officer, once appointed.

Myers holds a Bachelor of Science, master’s degree and doctorate from Iowa State University.

About Hormel Foods – Inspired People. Inspired Food.™

Hormel Foods Corporation, based in Austin, Minnesota, is a global branded food company with approximately $12 billion in annual revenue across more than 80 countries worldwide. Its brands include PLANTERS®, SKIPPY®, SPAM®, HORMEL® NATURAL CHOICE®, APPLEGATE®, JUSTIN’S®, WHOLLY®, HORMEL® BLACK LABEL®, COLUMBUS®, JENNIE-O® and more than 30 other beloved brands. The company is a member of the S&P 500 Index and the S&P 500 Dividend Aristocrats, was named one of the best companies to work for by U.S. News & World Report, one of America’s most responsible companies by Newsweek, recognized by TIME magazine as one of the World’s Best Companies and has received numerous other awards and accolades for its corporate responsibility and community service efforts. The company lives by its purpose statement — Inspired People. Inspired Food.™ — to bring some of the world’s most trusted and iconic brands to tables across the globe. For more information, visit hormelfoods.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hormel-foods-announces-leadership-change-in-supply-chain-302422300.html

SOURCE Hormel Foods Corporation

HOUSTON
, April 7, 2025 /PRNewswire/ — Stellus Capital Investment Corporation (the “Company”) (NYSE: SCM) announced that its Board of Directors has declared a monthly dividend of $0.1333 for each of April, May, and June, totaling $0.40 per share in the aggregate for the second quarter of 2025. The regular dividend of $0.40 per share will be paid to shareholders of record in May, June, and July 2025.

Summary of Second Quarter 2025 Regular Monthly Dividends

About Stellus Capital Investment Corporation

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) with a focus on investing through first lien (including unitranche) loans, often with a corresponding equity investment. The Company’s investment activities are managed by its investment adviser, Stellus Capital Management. To learn more about Stellus Capital Investment Corporation, visit www.stelluscapital.com under the “Public (SCIC)” link.

FORWARD-LOOKING STATEMENTS

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Capital Investment Corporation
W. Todd Huskinson, (713) 292-5414
Chief Financial Officer
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-capital-investment-corporation-announces-0-40-second-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-1333-in-may-june-and-july-2025–302422475.html

SOURCE Stellus Capital Investment Corporation

NEW YORK
, April 7, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline.

So what: If you purchased Ready Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Ready Capital class action, go to https://rosenlegal.com/submit-form/?case_id=36512 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) significant non-performing loans in its commercial real estate (“CRE”) portfolio were not likely to be collectible; (2) Ready Capital would fully reserve these problem loans in order to “stabilize” its CRE portfolio; (3) this was not accurately reflected in Ready Capital’s current expected credit loss or valuation allowances; (4) as a result, Ready Capital’s financial results would be adversely affected; and (5) as a result of the foregoing, Ready Capital’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Ready Capital class action, go to https://rosenlegal.com/submit-form/?case_id=36512 or https://rosenlegal.com/submit-form/?case_id=28116 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rc-investors-have-opportunity-to-lead-ready-capital-corporation-securities-fraud-lawsuit-302422358.html

SOURCE THE ROSEN LAW FIRM, P. A.

Finance Executive to Accelerate Growth and Extend Strong Leadership Team

PITTSBURGH
, April 7, 2025 /PRNewswire/ — The PNC Financial Services Group, Inc. (NYSE: PNC) today announced that its Board of Directors has unanimously appointed Mark Wiedman as president of the corporation and its wholly owned banking subsidiary, PNC Bank, National Association, effective immediately.

Wiedman will report to PNC Chairman and Chief Executive Officer William S. Demchak. PNC’s primary operating lines of business and the Regional Presidents Office will report to Wiedman.

“I’m thrilled Mark has joined us in this role,” said Demchak. “Banking today is nothing like your father’s bank – not even close. Mark brings deep experience from a fast-moving, tech-forward, consolidating industry that aligns perfectly with where we are headed, and which is why Mark is the right fit for this role. I have worked with Mark for 20 years, and we are fortunate that the timing was right for him to join our team.” 

PNC is executing a clear, growth-focused strategy backed by strategic investments and disciplined execution. In 2024, the bank successfully strengthened customer relationships and achieved positive operating leverage. PNC has significant opportunity to scale the bank to capitalize on this momentum, growing its client base through diversified products and services, leveraging technology for best-in-class service and security, and growing brand awareness and consideration by doing what is right for our customers, communities, employees and shareholders.

Wiedman was previously senior managing director at BlackRock and a member of the Global Executive Committee. He played a key role in driving organic growth and business transformation, while leading strategic initiatives both within and beyond the firm.

Wiedman was most recently the head of the Global Client Business responsible for BlackRock’s $11 trillion in commercial relationships, partnerships, and joint ventures across financial institutions and investors worldwide. Prior to that, he was global head of iShares and Index Investments and drove its growth from $500 billion to $1.7 trillion. Wiedman built his early career at BlackRock advising on capital markets and balance sheet issues, joining in 2004 to help start Financial Markets Advisory. He later led BlackRock’s emergency assistance to governments and financial institutions during the financial crisis. Wiedman also led BlackRock’s 2008 creation of Penny Mac and served on its board from 2008-2019. Before joining BlackRock, he was senior advisor to the Under Secretary for Domestic Finance at the U.S. Treasury. 

“PNC has earned one of the most exciting spots in U.S. finance, and I’m eager to join Bill and his team to help accelerate this company’s incredible growth journey,” said Wiedman. “The banking landscape is evolving fast. The winners will understand where customers and technology are heading and move there faster than the rest. Together with the team we will develop an even stronger franchise and culture – ensuring PNC is the best bank to do business with and the best place to build a career.” 

PNC Bank, National Association, is a member of The PNC Financial Services Group, Inc. (NYSE: PNC). PNC is one of the largest diversified financial services institutions in the United States, organized around its customers and communities for strong relationships and local delivery of retail and business banking including a full range of lending products; specialized services for corporations and government entities, including corporate banking, real estate finance and asset-based lending; wealth management and asset management. For information about PNC, visit www.pnc.com.

CONTACTS

MEDIA:

Anne Pace 
(631) 338-3268 
[email protected]  

INVESTORS:

Bryan Gill

(412) 768-4143
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mark-wiedman-joins-pnc-as-president-302422471.html

SOURCE The PNC Financial Services Group, Inc.

• Phase 2b study completed in
  amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline
• Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization
• Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025

CAMBRIDGE, Mass.
, April 7, 2025 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update.

Business highlights from 2024 and to date

• PrimeC achieved primary and secondary clinical endpoints in PARADIGM Phase 2b study investigating PrimeC in ALS (n=68) with data showing the following:
  – PrimeC slowed disease progression (measured by ALSFRS-R) by approximately 33% after 18 months (p=0.007)
  – PrimeC reduced likelihood of mortality, hospitalization and respiratory support, resulting in an overall 58% improvement in survival rates. 
  – PrimeC slowed functional decline, especially speaking and swallowing functions. 
  – PrimeC demonstrated favorable safety and tolerability profile, achieving the study’s primary endpoint. 
• Phase 3 study design for PrimeC for ALS aligned with FDA following Type C meeting. 
• Partnership discussions are continuing in order to advance PrimeC towards regulatory approval and eventual commercialization.  
• Plans to file for early commercialization for PrimeC in Canada, with an estimated potential market opportunity of $100m–$150m in peak annual revenues. 
• Key patent granted by U.S. Patent and Trademark Office (USPTO), extending the patent protection for the novel formulation of PrimeC until 2042.

“2024 was a year of significant clinical progress for NeuroSense,” stated NeuroSense CEO, Alon Ben-Noon. “We successfully completed our Phase 2b study for PrimeC in ALS, with data showing transformative results in a neurodegenerative indication of immense medical need. The results conclude with PrimeC’s disease-modifying potential and strongly support advancing PrimeC towards a Phase 3 study. With positive FDA feedback on the proposed study design, we are putting everything in place for the next stage of NeuroSense’s growth, driven by PrimeC’s continued clinical development.”

Financial Results

Research and development expenses for the years ended December 31, 2024 and 2023 were $5.7 million and $7.3 million, respectively. The decrease of $1.6, or 21.9%, was mainly attributed to a decrease in our expenses to subcontractors and consultants and a decrease in share-based payment expense.

General and administrative expenses for the years ended December 31, 2024 and 2023 were $4.2 million and $4.8 million, respectively. The decrease of $0.6, or 12.5%, was mainly attributed to a decrease in share-based compensation and insurance costs and a decrease in salaries and social benefit expenses mainly due to decrease in the number of employees which were offset by an increase in professional services expenses.

As of December 31, 2024, NeuroSense had cash of approximately $3.4 million.

A summary of NeuroSense’s consolidated financial results is included in the tables below.

A copy of the Company’s annual report on Form 20-F for the year ended December 31, 2024 has been filed with the U.S. Securities and Exchange Commission at https://www.sec.gov/ and posted on the Company’s investor relations website at https://neurosense.investorroom.com/sec-filings. The Company will deliver a hard copy of its annual report, including its complete audited financial statements, free of charge, to its shareholders upon request at [email protected].

 

 

 

 

 

 

 

 

About ALS
Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About PrimeC
PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC’s biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.

About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements 
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding ongoing partnership discussions, the timing of initiation of studies, regulatory filings, meetings and regulatory decisions, market potential and expected growth in the market. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the partnership discussions will not lead to execution of a definitive agreement, or that, if executed, will not lead to the current anticipated benefits to NeuroSense, a delay in the planned Phase 3 study for PrimeC in ALS, lower than anticipated market opportunity in Canada and elsewhere, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the development of PrimeC, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo – https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-reports-year-end-2024-financial-results-and-provides-business-updates-302422467.html

SOURCE NeuroSense